Zoran Rumboldt1, Howard A. Rowley2, Fred Steinberg3, Joseph A. Maldjian4, Jordi Ruscalleda5, Lars Gustafsson6, Stefano Bastianello7
1Department of Radiology,, Medical University of South Carolina, Charleston, SC, USA; 2Department of Radiology, UWHC, Madison, WI, USA; 3University MRI & Diagnostic Imaging Centers, Boca Raton, FL; 4Dept. of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC; 5Dept. of Neuroradiology, Hospital de la Santa Cruz y San Pablo, Barcelona, Spain; 6Dept. of Neuroradiology, Sahlgrenska University Hospital, Gothenburg, Sweden; 7Fondazione Istituto Neurologico Casimiro Mondino, Pavia, Italy
Forty-one patients with suspected brain tumors underwent two identical, randomized MRI exams at 3 Tesla; one enhanced with 0.1 mmol/kg gadobenate dimeglumine (MultiHance; Gd-BOPTA) and the other with 0.1 mmol/kg gadopentetate dimeglumine (Magnevist; Gd-DTPA). Three blinded readers evaluated matched image sets for qualitative (lesion delineation, lesion enhancement, global preference) and quantitative (LBR, CNR, % enhancement) lesion enhancement. Highly-significant preference for Gd-BOPTA was reported by each reader for all qualitative and quantitative end-points. The results confirm that the diagnostic superiority noted previously for 0.1 mmol/kg Gd-BOPTA relative to other gadolinium agents at 1.5 Tesla is maintained at 3 Tesla.